Impact of different diagnostic technologies for MRSA admission screening in hospitals – a decision tree analysis by unknown
RESEARCH Open Access
Impact of different diagnostic technologies
for MRSA admission screening in
hospitals – a decision tree analysis
Claudia Hübner1*, Nils-Olaf Hübner2,3, Christian Wegner2 and Steffen Flessa1
Abstract
Background: Hospital infections with multiresistant bacteria, e.g., Methicillin-resistant Staphylococcus aureus (MRSA),
cause heavy financial burden worldwide. Rapid and precise identification of MRSA carriage in combination with
targeted hygienic management are proven to be effective but incur relevant extra costs. Therefore, health care
providers have to decide which MRSA screening strategy and which diagnostic technology should be applied
according to economic criteria.
Aim: The aim of this study was to determine which MRSA admission screening and infection control management
strategy causes the lowest expected cost for a hospital. Focus was set on the Point-of-Care Testing (PoC).
Methods: A decision tree analytic cost model was developed, primarily based on data from peer-reviewed
literature. In addition, univariate sensitivity analyses of the different input parameters were conducted to study
the robustness of the results.
Findings: In the basic analysis, risk-based PoC screening showed the highest mean cost savings with 14.98 € per
admission in comparison to no screening. Rapid universal screening methods became favorable at high MRSA
prevalence, while in situations with low MRSA transmission rates omission of screening may be favorable.
Conclusion: Early detection of MRSA by rapid PoC or PCR technologies and consistent implementation of appropriate
hygienic measures lead to high economic efficiency of MRSA management. Whether general or targeted screening is
more efficient depends mainly on epidemiological and infrastructural parameters.
Keywords: Admission screening, Point-of-care, Hospital, Cost, Decision tree analysis, Methicillin-resistant
Staphylococcus aureus
Background
Infections with Methicillin-resistant Staphylococcus aureus
(MRSA) cause heavy financial burden on healthcare sys-
tems worldwide [1–3]. In particular, hospitals are highly
economically affected by the consequences [4]. About 5 %
of all hospital-acquired infections are caused by MRSA
[5]. Main cost drivers are prolongation of hospital stay
and contact precaution measures [6]. While the economic
impact on nosocomial MRSA acquisition is controversial,
it has been proven that rapid and precise identification of
MRSA carriage at hospital admission reduces turn-
around-time and thus the number of days in precaution-
ary isolation [7, 8].
Health care providers have to decide which screening
strategy to follow and which diagnostic technology to
use in consideration of medical and economic criteria.
The three main strategic options are universal screening,
targeted risk-based screening or the omission of screening.
Polymerase-Chain-Reaction (PCR), culture and Point-of-
Care (PoC) methods are the diagnostic technologies avail-
able on the market [9].
Several screening strategies have been studied in terms
of their cost-effectiveness [10–12]. However, little is
known about the impact of the concrete implementation
of a diagnostic test system in an MRSA hygiene manage-
ment of a hospital. Aim of this study was to determine
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which MRSA screening and management strategy causes
the lowest expected cost for a hospital with special focus
on PoC technology, a relatively new technology that is
not yet widely used for MRSA screening management.
Methods
Analytical model
The analysis is based on a multi-stage decision model
that assesses the expected cost of alternative MRSA ad-
mission screening and infection control management
strategies. The decision tree developed for this purpose is
shown in Fig. 1. The first branch is the decision between
“no screening” and “screening”. Here, the hospital has to
decide whether a screening strategy will be implemented
or not. If a screening is conducted, it must be decided
whether universal or targeted screening should be applied.
Universal screening means that all patients admitted to
the hospital are screened for MRSA. Targeted screening
includes only high risk patients. In Germany, the Com-
mission for Hospital Hygiene and Infection Prevention
(KRINKO) gives recommendations on risk factors (e.g.,
known MRSA patient history, previous hospitalization in
the last 12 months, contact with animal farms, chronic
care, previous antibiotic therapy in the last 6 months)
[13]. According to these recommendations, health facil-
ities can define additional factors based on individual
risk assessment. Further branches model the chosen
test method (PoC, PCR or culture methods) and whether
patients are taken under isolation while waiting for test re-
sults (pre-emptive isolation).
Finally the following 11 strategies were derived:
 no screening,
 universal screening with PoC testing
(cultural confirmation of positive test results),
 universal screening with cultural testing and
pre-emptive isolation,
 universal screening with cultural testing and
without pre-emptive isolation,
 universal screening with PCR testing
(cultural confirmation of positive test results)
and pre-emptive isolation until PCR result,
 universal screening with PCR testing
(cultural confirmation of positive test results)
and without pre-emptive isolation,
 targeted screening of high risk patients with
PoC testing (cultural confirmation of positive
test results),
Fig. 1 Model structure of the decision tree: 4-step-approach with decisions to (1) screening or not screening, (2) universal or targeted screening
of high risk patients, (3) PoC, PCR or culture test and (4) pre-emptive isolation or no pre-emptive isolation
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 targeted screening of high risk patients with cultural
testing and pre-emptive isolation,
 targeted screening of high risk patients with cultural
testing and without pre-emptive isolation,
 targeted screening of high risk patients with PCR
testing (cultural confirmation of positive test results)
and pre-emptive isolation until PCR result,
 targeted screening of high risk patients with PCR
testing (cultural confirmation of positive test results)
and without pre-emptive isolation.
Input parameter
As shown in Table 1, most data were taken from a previ-
ous literature review conducted by our working group
[14]. Values regarding the cross-transmission rates have
been updated by reassessment of the literature: RTno iso
(new: 0.0443, old: 0.01), RTiso (new: 0.0033, old: 0.0029).
The data of two more studies [15, 16] have been
incorporated, as they are examples of higher cross-
transmission rates, especially in situation without isola-
tion, which were previously in [14] under-represented.
Other data are based on in-house references of the Uni-
versity Medicine of Greifswald (UMG) and Mölnlycke
Health Care.
Assumptions
For the analytical model, several assumptions have been
made:
1. Positive MRSA test results by PCR or
PoC but must be confirmed by a culture test.
2. Negative MRSA test results by PCR
or PoC will not be confirmed by a
culture test.
Table 1 Definition and quantification of input parameter
Parameter Description Value Reference
Pt MRSA prevalence of all inpatients 3.075 % [14]
Pr MRSA prevalence of high-risk inpatients 11.94 % [14]
Pn. i. MRSA prevalence of patients without indication for a targeted screening 2.09 % Calculation based on in-house data (UMG)
a
RTno iso Rate of MRSA transmission not in isolation per day 0.0443 [14], updated with [15, 16]
RTiso Rate of MRSA transmission in isolation per day 0.0033 [14], updated with [15, 16]
SenPoC Sensitivity of PoC method 95 % In-house data (mölnlycke hc)
SenPCR Sensitivity of PCR method 91.09 % [14]
Sencul Sensitivity of culture method 88.73 % [14]
SPPoC Specificity of PoC method 97.5 % In-house data (mölnlycke hc)
SPPCR Specificity of PCR method 95.79 % [14]
SPcul Specificity of culture method 93.23 % [14]
Cpre iso Average costs for pre-emptive isolation per day 62.77 € [14]
CMRSA Average costs per MRSA case per day 506.92 € [14]
∅ LOSMRSA Average length of stay of MRSA patients in days 24.88 [14]
TPoC Turn-around time of PoC method in days 0.01389 [9]
TPCR Turn-around time of PCR method in days 0.29 In-house data (UMG)
Tcul Turn-around time of culture method in days 2.5 In-house data (UMG)
CPoC Costs for a single PoC test 30 € [9]
CPCR Costs for a single PCR test 20.50 € [14]
Ccul pos Costs for a single culture test with positive result 24.10 € [14]
Ccul neg Costs for a single culture test with negative result 6.40 € [14]
Cf Costs for follow-up screening 6.40 € Costs of a negative culture test are assumed
Cc Costs for screening a contact patient 6.40 € Costs of a negative culture test are assumed
Patc Number of contact patients 2 calculation based on in-house data (UMG)
∅ LOSreg Average length of stay of regular patients in days 8 [14]
Patt Number of total inpatients per year 35,322 In-house data (UMG)
Patrisk Number of high-risk patients per year 3,532 In-house data (UMG)
Patn. i. Number of patients without indication for a targeted screening per year 31,790 In-house data (UMG)
aUMG University Medicine Greifswald
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3. If the MRSA test is negative, pre-emptive isolation
is immediately discontinued and no further steps
are taken.
4. Due to the short turn-around-time of the PoC test
no pre-emptive isolation is taken into account.
5. Decision tree branches end after MRSA is excluded
or after MRSA eradication treatment and follow-up
screening has been conducted.
6. Cultural test method is applied for follow-up
and contact-patient screening. These test results
assumed to be negative.
7. Secondary MRSA cases (due to transmission events
from index patients) are included in the analysis and
causes costs of MRSA infections.
8. Tertiary MRSA cases (due to transmission events
from secondary patients) are not included in the
analysis.
9. Screening of contact persons is only necessary if no
pre-emptive isolation of MRSA patient is conducted.
Cost calculation
Expected costs for each screening strategy are calculated
in the decision model. Calculations are based on the
values of input parameters stated in Table 1. The principle
is demonstrated exemplary for targeted PCR screening
with pre-emptive isolation measures by the following for-
mulas of Table 2.
Additionally, cost differences of each strategy to the coun-
terfactual strategy "no screening" were determined per
admission to compare all screening strategies. Advantageous
screening strategies resulted in cost savings (positive net
benefit), unfavorable screening strategies in additional costs.
Sensitivity analyses
Univariate sensitivity analyses of the parameters “Rate of
nosocomial MRSA transmission” and “MRSA preva-
lence” were conducted. This allows simulating scenarios
of hospitals with various structure and patient profiles
(primary care vs. specialist care), departmental analyses
(ICUs vs. general wards) or the consideration of MRSA
outbreak situations.
MRSA transmission rate not in isolation was varied be-
tween 0.001 and 0.121 transmission per day. A division of
each varied value by the factor 13 determined the corre-
sponding values of MRSA transmission rate in isolation.
This ratio of 1:13 resulted as the average of all included
references (Table 1).
With regard to MRSA prevalence, an interrelation be-
tween the parameters “MRSA prevalence of all inpa-
tients” and “MRSA prevalence of high-risk inpatients” is
implied. Therefore, three scenarios at different MRSA
Table 2 Calculation of expected costs in decision model (using the example of strategy “targeted PCR screening with pre-emptive
isolation measures”)
Combinations of true and tested MRSA status
of screened patients
Costs per patient*: Number of patients*:
MRSA positive CPCR + Cculpos + Cpreiso* (TPCR + Tcul) + CMRSA* (Ø LOSMRSA- TPCR-Tcul) + Cc*Patc + Ø
LOSMRSA* RTiso* CMRSA* Ø LOSMRSA
Patrisk* Prisk* SenPCR*
SenculPCR (+) and culture (+)→ true positive
MRSA negative CPCR + Cculpos + Cpreiso* (TPCR + Tcul) + CMRSA* (Ø LOSMRSA- TPCR-Tcul) + Cc*Patc Patrisk* (1 - Prisk) *
(1 - SPPCR) * (1 - SPcul)but PCR (+) and culture (+)→ false
positive
MRSA positive CPCR + Cculneg + Cpreiso* (TPCR + Tcul) + [(Ø LOSMRSA- TPCR-Tcul) * RTnoiso + (TPCR +
Tcul) * RTiso] * CMRSA* Ø LOSMRSA
Patrisk* Prisk* SenPCR*
(1 - Sencul)PCR (+), no confirmation because culture
(-)→ false negative
MRSA negative CPCR + Cculneg + Cpreiso* (TPCR + Tcul) Patrisk* (1 - Prisk) *
(1 - SPPCR) * SPculPCR (+), no confirmation because culture
(-)→ false positive
MRSA positive CPCR + Cpreiso* TPCR + [(Ø LOSMRSA - TPCR) * RTnoiso* + TPCR* RTiso] * CMRSA* Ø
LOSMRSA
Patrisk* Prisk*
(1 - SenPCR)but PCR (-), no culture test conducted
→ false negative
MRSA negative CPCR + Cpreiso* TPCR Patrisk* (1 - Prisk) *
SPPCRPCR (-), no culture rest conducted→ true
negative
No high-risk patients
(screening is not indicate)
Cost due to transmission (of MRSA-Patients, who were not screened) Number of patients
MRSA positive Ø LOSMRSA* RTnoiso* CMRSA* Ø LOSMRSA Patn.i.* Pn.i.
MRSA negative no costs Patn.i.* (1-Pn.i.)
*note: Variables are explained in Table 1
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prevalences (all inpatients/high-risk inpatients) were
tested: low prevalence (0.5 %/3.5 %), middle preva-




Targeted MRSA screening and hygiene management re-
gimes using PoC or PCR technologies proved to be the
most cost minimizing strategies in basic analysis. Aver-
age costs of all three methods were calculated between
468 and 470 € per admission. Strictly, risk-based (tar-
geted) PoC screening showed the highest cost saving
with a net benefit of 14.98 € per admission compared to
“no screening”. However, deviations between the different
screening regimes were quite moderate with the exception
of universal cultural test methods. Cultural testing in com-
bination with or without pre-emptive isolation caused im-
mensely higher costs per admission compared to the
omission of any MRSA-screening with additional costs of
264.40 € (no pre-emptive isolation) or 449.81 € (pre-emp-
tive isolation) per admission, respectively (Table 3).
Sensitivity analyses
Rate of MRSA transmission
Curves representing the cost of the different screening
regimes independence rates of nosocomial MRSA trans-
mission not in isolation between 0.001 and 0.121 per day
are shown in Fig. 2. The average cost per admission rises
continuously with the increase of the MRSA transmis-
sion rate in all screening strategies. Three intervals de-
pending on nosocomial MRSA transmission rate can be
distinguished: Below a transmission rate of 0.04322
transmissions per day the omission of any screening
method is the least costly strategy. Rapid (PoC or PCR)
targeted screening regimens are most advantageous
between a rate of 0.04322 and 0.05038 transmissions per
day. This span corresponds to the range of MRSA trans-
mission rates of normal wards in hospitals in Central
Europe [17]. Universal rapid screening regimens con-
ducted by PoC or PCR cause the lowest cost for a hos-
pital above a transmission rate of 0.05038. This range
can be assigned to high-risk areas in hospitals such as
intensive care units or to outbreak situations [15, 18].
MRSA prevalence
Differences in the favorability of the specific diagnostic
technologies for the three scenarios with low, medium
and high MRSA prevalence are shown in Fig. 3. While at
a low MRSA prevalence only rapid targeted screening
strategies were beneficial versus “no screening”, ever
more regimes became advantageous with increasing
MRSA prevalence. At a high MRSA prevalence, 7 of 10
strategies are favorable. Here, “universal PoC screening”
showed the highest cost savings with 77.22 € per admis-
sion compared to “no screening”, followed by the two
universal PCR methods (with and without pre-emptive
isolation measures).
Discussion
The study shows a decision tree analysis to evaluate vari-
ous MRSA admission screening methods as part of hy-
giene management regimes in hospitals. To our best
knowledge, Point-of-Care technology is included in such
an analytic model for the first time. Our results deter-
mine that rapid test methods (PoC or PCR) are always
cost-minimizing in comparison to culture methods. By
contrast, the decision on a universal or a risk-based
method or the omission of any screening is highly
dependent on epidemiological and infrastructural condi-
tions regarding healthcare providers.
Table 3 Results of basic analysis for all 11 screening strategies: average costs per admission and cost savings (net benefits) in
comparison to strategy “no screening”
Screening strategy Average cost per admission Cost-saving to "no screening"a
PoC (target) 468.14 € −14.98 €
PCR (target, no isolation) 469.30 € −13.82 €
PCR (target, isolation) 469.80 € −13.32 €
Culture (target, no isolation) 501.66 € 18.54 €
Culture (target, isolation) 506.90 € 23.78 €
No screening 483.12 € 0.00 €
PoC (universal) 478.18 € −4.94 €
PCR (universal, no isolation) 478.75 € −4.37 €
PCR (universal, isolation) 500.07 € 16.95 €
Culture (universal, no isolation) 741.36 € 258.24 €
Culture (universal, isolation) 925.93 € 442.81 €
aA negative value indicates a positive net benefit
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The MRSA cross transmission rate per day has been
found as a very influential parameter by the sensitivity
analysis. Based on the literature review of Tübbicke et
al. [14] the basic analysis was calculated with an average
transmission rate of 0.0443 transmissions per day. This
coincides with the mid-interval of our sensitivity analysis
(Fig. 3), in which the selective PoC strategy is most cost
effective. However, the literature analysis shows outliers
to both sides. For example, Raboud et al. [19] declared a
very low rate of 0.00137 transmissions per day, while
Jernignan et al. [18] showed a significantly higher rate
with 0.140 transmissions per day. The latter study has
been conducted with the particular patient clientele of
neonatology. Other studies with a high cross trans-
mission rate analyse outbreaks of MRSA [15, 16, 18].
Our study results demonstrate that in defined hospital
departments (e.g., neonatology, ICUs, oncology, trans-
fusion medicine, burn units) or in outbreak situations
universal screening is not only medically but also
economically viable.
Variations of MRSA prevalence have also strongly in-
fluenced test results. An increase of the MRSA preva-
lence tends to favor universal screening strategies, while
in situations at lower prevalence (basic analysis) targeted
risk-based methods are preferable. In line with literature,
this underlines the regional epidemiology as an import-
ant decision [10]. In most of these studies, authors con-
cluded risk-based screening to be cost-effective. Creamer
et al. proved their statement in a backward stepwise lo-
gistic regression model by identifying defined risk factors
[20]. Bühlmann et al. justified the restricted use of PCR
methods with high costs and thus limited the implemen-
tation of pre-emptive isolation measures to high risk pa-
tients [21]. However, they also acknowledged that it
might be different in settings with higher MRSA preva-
lence and transmission rates as shown in our sensitivity
analyses. Shenoy et al. concluded from their randomized
controlled trial that active PCR screening leads to a
rapid discontinuation of contact precautions for MRSA,
which can alleviate capacity constraints [22]. At the
Fig. 2 Sensitivity analysis: Graph of average cost per admission at different rates of MRSA transmission per day without isolation from 0.001 to
0.121 (corresponding rates of MRSA transmission per day in isolation from 0.0001 to 0.0093)
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same time the authors also stressed that the net benefit
of a screening program might depend on institutional
characteristics including MRSA prevalence.
Our analysis also illustrates that the price of the test
systems is not decisive. In contrast, the admission
screening must be evaluated as part of all hygienic pro-
cesses of a hospital. Early detection of MRSA by PoC or
PCR diagnostics with their short turn-around-times and
the consistent implementation of appropriate measures
result in a high economic efficiency of MRSA manage-
ment. Consequently, screening strategies with the cheaper
culture methods prove comparatively unfavorable due to
long turn-around times.
Our study has several limitations. First, the data quality
needs to be critically examined. Most data was based on
published international studies collected by a systematic
literature research. For parameter where no sufficient in-
formation was found in the literature, we supplemented
in-house data or made assumptions in consultation with
hygiene experts. No probabilistic multivariate sensitivity
analysis was performed. Instead, robustness of test results
was proven by univariate sensitivity analyses and pointed
to the dependence of individual parameters. Our analysis
includes only transmissions from index patients to sec-
ondary cases, while transmissions from secondary cases
and so on were excluded, thus underestimating the costs
of transmissions. On the other hand, we assumed that all
secondary cases cause costs due to MRSA infection for
the hospital. Again, this is a simplification that may over-
estimate costs of transmission.
We did not simulate the effect of pre-test factors that
may influence the sensitivity of the screening, e.g., use of
different swabs or multi-site swabbing. The literature
demonstrates that additional MRSA screening at extra-
nasal sites increases MRSA detection by one-third com-
pared to nares screening alone [23]. However, most
PCRs and PoCs are not validated for multi-site testing
and KRINKO recommendations favor nasal screening.
Fig. 3 Scenario analysis: Column chart of average cost savings per admission in comparison to strategy “no screening” at 3 different MRSA
prevalence scenarios (first value indicates prevalence of all patients, second value indicates prevalence of high risk patients)
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For this reason, we have limited our model on the nares
screening.
Finally, the analysis was conducted from the perspec-
tive of the healthcare provider and assessed its expected
costs. A macroeconomic analysis may come to different
statements, since more cost and benefit effects of pa-
tients or health insurances must be included. An import-
ant preliminary work for this purpose is the computer
simulation study by Lee et al., which determined the
economic impact of the implementation of a universal
MRSA surveillance from the societal and third party-
payer perspectives [12]. The extension of the analytical
model is a potential research question for future work,
especially in terms of inter-institutional cooperation be-
tween different healthcare providers and the economic
evaluation of pre-admission MRSA screening.
Conclusion
In summary, we developed an analytical model as decision-
making tool that allows recommendations for the imple-
mentation of a cost-effective MRSA admission screening
and infection control management strategy. Obviously,
the results demonstrate the economic advantageous-
ness of modern MRSA diagnostic techniques, particu-
larly the Point-of-Care technology. However, it is clear
that there is no silver bullet of uniform screening manage-
ment, but that the knowledge of individual epidemio-
logical and infrastructure parameters of the whole hospital
or specific areas is crucial.
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